Patents
Literature
4 results about "ERBB3" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ERBB3 gene. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases. The kinase-impaired ErbB3 is known to form active heterodimers with other members of the ErbB family, most notably the ligand binding-impaired ErbB2.
Humanised sequence for the generation of Anti-ERBB3 / her3 antibodies
PCT designated stageWO2026088233A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsTyrosineIntravenous gammaglobulin
The present invention relates to a humanised sequence binding the receptor tyrosine kinase ErbB3 / HER3 for the generation of anti-ErbB3 / HER3 antibodies in different formats, such as, for example, immunoglobulins, bispecific antibodies, in particular bispecific T-cell engagers, or antibody-drug conjugates (ADCs) or fusion immunoproteins, for the treatment of solid tumours depending on the expression of the ErbB3 receptor.
Owner:TAKIS
Means and methods for treating castration-resistant prostate cancer
PendingUS20260167740A1Organic active ingredientsAntibody ingredientsAntiendomysial antibodiesBinding site
The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.
Owner:MERUS NV
AN ERBB3 BINDING SPECIFIC ANTIBODIES AND USE OF THEM
ActiveDE602016094833T2Organic active ingredientsAntibody ingredientsAntiendomysial antibodiesBiochemistry
Owner:ISU ABXIS
Anti-ERBB3 antibodies or their antigen-binding fragments and their pharmaceutical uses
This relates to anti-ERBB3 antibodies or their antigen-binding fragments and their pharmaceutical uses, particularly to fully human antibodies against the ERBB3 receptor or their antigen-binding fragments and their pharmaceutical uses. It also includes pharmaceutical compositions comprising fully human anti-ERBB3 antibodies or their antigen-binding fragments, and their use as anticancer drugs.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1